momelotinib
momelotinib: developed by 1 company · 4 clinical trials tracked.
momelotinib evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could momelotinib → SRRA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 2 study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Sierra Oncology, Inc. (SRRA) | Phase 3 |
Clinical Trials (4)
Phase Ib/II Study Of Revumenib As Monotherapy Or In Combination With Jak Inhibitors In Patients With Myelofibrosis
Primary endpoint: Dose limiting toxicity (DLT)
A Pilot Study of Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (M-HArbOr)
Primary endpoint: Number of participants who achieve a complete response
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Primary endpoint: Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
Primary endpoint: Part 1, Part 1b (US Only): Number of Participants With Dose Limiting Toxicity (DLT)
Frequently asked questions
Who is developing momelotinib?
momelotinib is being developed by Sierra Oncology, Inc..
How many clinical trials involve momelotinib?
BioSniper tracks 4 clinical trials involving momelotinib.